6897527
Last Update Posted: 2025-03-27
Recruiting has not begun
Females accepted | 18 Years + |
100 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.
Eligibility
Relevant conditions:
Neoplasms, Endometrial
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov